Twist Bioscience (TWST) Operating Leases (2019 - 2026)

Twist Bioscience (TWST) has 8 years of Operating Leases data on file, last reported at $85.4 million in Q1 2026.

• Operating Leases for Q1 2026 came in at $85.4 million, up 31.22% year-over-year; the trailing twelve-month figure through Mar 2026 was $85.4 million (up 31.22% YoY), and the FY2025 annual result was $61.8 million, down 12.06% from the prior year.
• Operating Leases was little changed at $85.4 million in Q1 2026 per TWST's latest filing, from $85.8 million in the prior quarter.
• Over five years, Operating Leases peaked at $94.0 million in Q4 2022 and troughed at $61.8 million in Q3 2025.
• A 5-year average of $78.6 million and a median of $79.2 million in 2023 frame the typical range for Operating Leases.
• The sharpest annual moves came in 2022 and 2025: Operating Leases soared 194.44% in 2022, then decreased 28.14% in 2025.
• A 5-year view of Operating Leases shows it stood at $94.0 million in 2022, then retreated by 2.23% to $91.9 million in 2023, then fell by 26.44% to $67.6 million in 2024, then gained by 26.96% to $85.8 million in 2025, then decreased by 0.48% to $85.4 million in 2026.
• Business Quant data shows TWST's Operating Leases at $85.4 million in Q1 2026, $85.8 million in Q4 2025, and $61.8 million in Q3 2025.